Peter Ganly

Peter Ganly

UNVERIFIED PROFILE

Are you Peter Ganly?   Register this Author

Register author
Peter Ganly

Peter Ganly

Publications by authors named "Peter Ganly"

Are you Peter Ganly?   Register this Author

22Publications

701Reads

11Profile Views

Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centre.

Intern Med J 2019 05;49(5):598-606

Haematology Research Group, Christchurch Hospital and Department of Pathology and Biomedical Science, Christchurch, New Zealand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/imj.14155DOI Listing
May 2019

Genomic Classification and Prognosis in Acute Myeloid Leukemia.

N Engl J Med 2016 Jun;374(23):2209-2221

Cancer Genome Project, Wellcome Trust Sanger Institute (E.P., M.G., N.D.R., N.B., G.G., P.V.L., I.M., L.M., S.M., S.O., K.R., D.R.J., J.W.T., A.P.B., P.J.C.), and the European Bioinformatics Institute, European Molecular Biology Laboratory (EMBL-EBI) (M.G.), Hinxton, the Centre for Evolution and Cancer, Institute of Cancer Research, London (N.E.P., M.F.G.), and the Department of Haematology, University of Cambridge, Cambridge (N.B.) - all in the United Kingdom; the Departments of Epidemiology and Biostatistics and Cancer Biology, the Center for Molecular Oncology and the Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York (E.P.); the Department of Internal Medicine III, Ulm University, Ulm (L.B., V.I.G., P.P., K.D., R.F.S., H.D.), and the Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover (M.H., F.T., A.G.) - both in Germany; the Division of Hematology, Fondazione IRCCS, Istituto Nazionale dei Tumori, and Department of Oncology and Onco-Hematology, University of Milan, Milan (N.B.); the Department of Human Genetics, University of Leuven, Leuven, Belgium (P.V.L.); and the Department of Pathology, University of Otago, Christchurch, New Zealand (P.G., P.J.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1516192DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979995PMC
June 2016

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

N Engl J Med 2016 Apr;374(17):1621-34

From University Hospital Hôtel Dieu, Nantes (P.M., C.T.), the Department of Hematology, Institut Paoli-Calmettes, Marseille (A.-M.S.), and the Department of Hematology and Cell Therapy, Hospital Saint Antoine, Paris (L.G.) - all in France; the Department of Haematology and Stem Cell Transplantation, St. István and St. László Hospital, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary (T.M.); the Department of Haemato-oncology and Bone Marrow Transplantation, Medical University of Lublin, and St. John's Cancer Center, Lublin, Poland (N.G.); Southern Alberta Cancer Research Institute, University of Calgary, Calgary (N.J.B.), and the Division of Hematology, Department of Medicine, University of Alberta, Edmonton (I.S.) - both in Canada; the Department of Hematology, Skåne University Hospital, Lund University, Lund, Sweden (M.H.); Hematology and Oncology, University Hospital Brno, Brno, Czech Republic (L.P.); the Department of Haematology, Christchurch Hospital, Christchurch (P. Ganly), the Department of Haematology, Palmerston North Hospital, Palmerston North, Manawatu (B.W.B.), the Department of Haematology, Middlemore Hospital, Auckland (S.R.J.), and the Department of Haematology, North Shore Hospital, Auckland (D.R.S.) - all in New Zealand; the Department of Hematology, University Hospital Rigshospitalet, Copenhagen (P. Gimsing); Myeloma Unit, Division of Hematology, University of Turin, Turin (A.P.), and Seràgnoli Institute of Haematology, Bologna University School of Medicine, St. Orsola-Malpighi University Hospital, Bologna (M.C.) - both in Italy; the Division of Hematology, Mayo Clinic, Rochester, MN (S.K., F.K.B.); and Dana-Farber Cancer Institute, Boston (J.P.L., P.G.R.), and Millennium Pharmaceuticals, Cambridge (D.T.B., J.L., A.D.B., A.-M.H., H.V.) - both in Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1516282DOI Listing
April 2016

Development of T-cell lymphomas with an activated cytotoxic immunophenotype, including anaplastic large cell lymphomas, in patients with chronic lymphocytic leukemia: a series of six cases.

Leuk Lymphoma 2015 Mar 17;56(3):774-8. Epub 2014 Jul 17.

Canterbury Health Laboratories, Canterbury District Health Board , Christchurch , New Zealand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.927460DOI Listing
March 2015

Not walking or communicating--is all well?

Lancet 2008 Dec;372(9655):2086

Canterbury Health Laboratories, Christchurch Hospital, Christchurch, New Zealand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(08)61870-XDOI Listing
December 2008

A prospective double-blind randomized trial comparing intraluminal ethanol with heparinized saline for the prevention of catheter-associated bloodstream infection in immunosuppressed haematology patients.

J Antimicrob Chemother 2008 Oct 11;62(4):809-15. Epub 2008 Jul 11.

Department of Pathology, Christchurch School of Medicine and Health Sciences, Otago University, Christchurch, New Zealand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jac/dkn284DOI Listing
October 2008

Written advice can provide a safe and acceptable alternative to new patient assessment for selected referrals to haematologists.

Med J Aust 2008 Jan;188(1):9-12

Department of Haematology, Canterbury Health Laboratories and Christchurch Hospital, Christchurch, New Zealand.

View Article

Download full-text PDF

Source
January 2008

Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.

Am J Hematol 2007 Jan;82(1):80-2

Cancer Genetics Research Group, Christchurch School of Medicine and Health Science, Christchurch, New Zealand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.20721DOI Listing
January 2007

Treatment with intravenous immunoglobulin is not a panacea but should be limited to those who can benefit.

N Z Med J 2006 Dec 1;119(1246):U2335. Epub 2006 Dec 1.

View Article

Download full-text PDF

Source
December 2006

Translocation (5;10)(q22;q24) in a case of acute lymphoblastic leukemia.

Cancer Genet Cytogenet 2006 Feb;165(1):36-40

Cancer Genetics Research Group, Department of Pathology, Christchurch School of Medicine & Health Sciences, PO Box 4345, University of Otago, Christchurch, New Zealand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cancergencyto.2005.08.008DOI Listing
February 2006

Familial mutations of the transcription factor RUNX1 (AML1, CBFA2) predispose to acute myeloid leukemia.

Leuk Lymphoma 2004 Jan;45(1):1-10

Cancer Genetics Research Group, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch, New Zealand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1042819031000139611DOI Listing
January 2004

Fibrinogen Hillsborough: a novel gammaGly309Asp dysfibrinogen with impaired clotting.

Blood 2002 May;99(10):3597-601

Molecular Pathology Laboratory, Canterbury Health Laboratories, Christchurch Hospital, Christchurch, New Zealand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.v99.10.3597DOI Listing
May 2002